Decades ago, doctors created a test to determine which breast cancer patients should receive hormone therapy. Now, ...

Thousands of men in England living with advanced prostate cancer are poised to benefit from a new life-extending drug, ...

Akeega, an oral dual mechanism therapy pairing niraparib with abiraterone, has won a positive committee opinion in Europe for ...

Prostate cancer is the second-most common cancer in men. A new study from Thomas Jefferson University uncovered a new potential therapeutic target in tiny molecules called tRNA halves.

Prostate cancer (PCa) is one of the most common malignant tumors among men worldwide. Following androgen deprivation therapy ...

Investigators tested a new neoadjuvant immunotherapy to fight prostate cancer using a virus-mimicking drug to activate the immune system.

Men with prostate cancer who get hormone therapy experience hot flashes, where they experience intense and sudden heat and ...

A national clinical trial led by the Alliance for Clinical Trials in Oncology has found that oxybutynin, a drug often used to ...

A Registrational Phase 2 clinical trial has been initiated in Japan for patients with PSMA-positive metastatic castration-resistant prostate ...

On World Cancer Day 2026, oncologists spoke about the early signs of prostate cancer, which are often mistaken for ...

Radiation therapy (also called radiotherapy) uses high-energy beams or subatomic particles to damage the DNA inside prostate cancer cells. After enough damage, the cells cannot multiply, and they die.